Corbus Q1 net loss widens to $17.7M; in-licenses CRB-701 Nectin-4 ADC

Corbus Pharmaceuticals Holdings, Inc.

2023-Q1 EPS reported -$4.24

Net loss of $17.7M ($4.24 per share) vs $9.4M ($2.26) in Q1 2022.
Operating expenses rose $8.8M to $17.3M, driven by $7.5M CRB-701 license upfront.
Cash and investments $44.2M; runway expected through Q2 2024.
In-licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 in China, US trial by mid-2024.
CRB-601 IND on track for H2 2023; Dr. Yong Ben appointed to board March 1.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2023 results: net income a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, EPS a net loss per diluted share of $4.24.

Period: the three months ended March 31, 2023
Net income: a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24
EPS: a net loss per diluted share of $4.24
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.